title: Effect of beraprost sodium on peripheral circulatory disturbances induced by various stimuli.
abstract: Effects of beraprost sodium (sodium(+/-)-(1R*,2R*,3aS*,8bS*)-2,3,3a,8b-tetrahydro-2-hydr oxy-1- [(E)-(3S*)-3-hydroxy-4-methyl-octen-6-ynyl]-1H-cyclopenta[b] benzofuran- 5-butyrate, TRK-100), a stable prostacyclin analogue, on the peripheral circulatory disturbances induced by various vasoconstrictive stimuli were studied. Orally administered beraprost sodium (10, 30 micrograms/kg) caused increase in skin blood flow in anesthetized rats and rise in skin temperature in conscious rats. Intravenously administered beraprost sodium (0.01-0.3 microgram/kg) reduced the recovery time of decreased pulse pressure by topical cooling of the leg in anesthetized rats. In conscious rabbits, intravenous infusion of beraprost sodium (10 micrograms/kg/min) inhibited the fluctuation of ear artery diameter, and dilated the ear artery and vein, resulting in a rise in the ear temperature. In anesthetized dogs, intravenously administered beraprost sodium (0.313-5 micrograms/kg) caused decrease in femoral blood flow and muscle blood flow in the hindlimb, however, it caused increase in skin blood flow at the hind leg instep. Furthermore, intra-arterially administered beraprost sodium (0.1-0.3 microgram/kg/min) under stimulation of lumbar sympathetic nerve caused increase in femoral artery blood flow and selective increase in the skin blood flow without affecting muscle blood flow.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Toray Industries, Inc., Basic Research Laboratories, Kanagawa, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Nishio
authors.forename: N
authors.initials: N
authors.lastname: Yamada
authors.forename: T
authors.initials: T
authors.lastname: Endoh
authors.forename: M
authors.initials: M
authors.lastname: Isogaya
authors.forename: Y
authors.initials: Y
authors.lastname: Fukatsu
authors.forename: S
authors.initials: S
authors.lastname: Nishimura
authors.forename: N
authors.initials: N
authors.lastname: Kanai
authors.forename: T
authors.initials: T
authors.lastname: Umetsu
mesh_terms: D000527:Alprostadil / Q000494:pharmacology; D000818:Animals; D004285:Dogs; D004431:Ear, External / Q000098:blood supply; D011464:Epoprostenol / Q000494:pharmacology* / Q000031:analogs & derivatives; D005263:Femoral Artery / Q000187:drug effects; D008297:Male; D009132:Muscles / Q000098:blood supply; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D011817:Rabbits; D051381:Rats; D011919:Rats, Inbred Strains; D012039:Regional Blood Flow / Q000187:drug effects*; D012867:Skin / Q000098:blood supply; D012881:Skin Temperature / Q000187:drug effects; D013564:Sympathetic Nervous System / Q000187:drug effects / Q000502:physiology; D014662:Vasoconstrictor Agents / Q000494:pharmacology
chemical_list: D010975:Platelet Aggregation Inhibitors; D014662:Vasoconstrictor Agents; C048081:beraprost; D011464:Epoprostenol; D000527:Alprostadil